ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis → Buy Friday. Sell Monday. (From WealthPress) (Ad) Free NEU Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neuren Pharmaceuticals alerts: Email Address Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Neuren Pharmaceuticals Stock (ASX:NEU)Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More Ad Huge AlertsThis 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here NEU Stock News HeadlinesMay 9, 2024 | msn.comWhy this high-flying ASX 200 healthcare stock just crashed 11%April 3, 2024 | msn.comASX loses 1.3% on back of Wall Street decline, gold price hits new high and the world's richest people are getting richer — as it happenedMay 11, 2024 | WealthPress (Ad)Buy Friday. Sell Monday. A 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend.April 1, 2024 | finance.yahoo.comHere's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of InvestorsMarch 26, 2024 | uk.finance.yahoo.com20 Biggest Health Care Companies in Australia, 2024March 18, 2024 | fool.com.auThe best ASX shares to invest $500 in right nowMarch 11, 2024 | fool.com.au$10k of savings? I'd buy these ASX 200 shares to grow my moneyMarch 3, 2024 | finance.yahoo.comNeuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their ModelsMay 11, 2024 | WealthPress (Ad)Buy Friday. Sell Monday. A 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend.February 29, 2024 | fool.com.auWhat's with the Neuren Pharmaceuticals share price today?February 28, 2024 | msn.comInflation remains at two-year low, Optus sacks extra 200 staff, Sony terminates 8pc of workforce, ASX finishes flat — as it happenedFebruary 28, 2024 | fool.com.auWhy is this ASX 200 pharmaceuticals stock crashing 15% today?February 16, 2024 | msn.comNeuren (NEU) Shares Plunge as Short Seller Targets Partner AcadiaFebruary 15, 2024 | fool.com.auThis ASX 200 healthcare share is diving 13% as short sellers take aimJanuary 18, 2024 | forbes.comStock Market Outlook In 2024January 15, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Clinuvel Pharmaceuticals Limited (CLVLF)January 12, 2024 | fool.com.au3 pharma shares outshining the ASX index todayJanuary 8, 2024 | fool.com.auThe Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?January 6, 2024 | fool.com.auThe No. 1 ASX 200 shares of each market sector in 2023January 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Innovent Biologics (IVBXF), Telix Pharmaceuticals Ltd. (TLPPF)December 26, 2023 | finance.yahoo.comAn Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 44% UndervaluedDecember 22, 2023 | fool.com.auWhy Boss Energy, Lynas, Neuren, and Ora Banda shares are rising todayDecember 19, 2023 | au.investing.comNeuren Pharmaceuticals' shares surge on positive Phase 2 clinical trial resultsDecember 18, 2023 | fool.com.auGuess which ASX 200 stock was just upgraded and tipped to rise 20%+December 17, 2023 | fool.com.auWhy is this ASX 200 healthcare stock surging 32% on Monday?December 13, 2023 | finance.yahoo.comAustralia Shares Rise, Helped by Healthcare StocksDecember 10, 2023 | afr.comNew fund targets companies battered by market doubtsSee More Headlines Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today5/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:NEU CUSIPN/A CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,105Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$1.20 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$157.08 million Net Margins67.72% Pretax MarginN/A Return on Equity127.30% Return on Assets85.52% Debt Debt-to-Equity RatioN/A Current Ratio5.78 Quick Ratio31.54 Sales & Book Value Annual Sales$231.94 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.61 per share Price / BookN/AMiscellaneous Outstanding Shares129,950,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.99 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Jonathan Charles Pilcher A.C.A.ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive DirectorMs. Lauren Frazer C.A.CFO & Company SecretaryMr. Lawrence Glass BA (Biology)Chief Science OfficerMr. Gerry ZhaoVice President of Corporate DevelopmentDr. Liza A. Squires M.D.Chief Medical OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersJoseph(Joe) BasileBought 5,000 shares on 9/13/2023Total: $59,950.00 ($11.99/share)Trevor ScottSold 1,175,000 sharesTotal: $15.28 M ($13.00/share) NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) announced its quarterly earnings data on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 127.30% and a net margin of 67.72%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT) and Alkane Resources (ALK). This page (ASX:NEU) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
